VARUBI J Code: J8670

Drug & Product Overview

HCPCS Descriptor Rolapitant, oral, 1 mg

HCPCS Added Date January 1, 2017

Manufacturer Tersera Therapeutics Llc

Route of Administration Oral

Generic Status Single-Source; Branded

Dosage Form Tablet

About VARUBI

Varubi is a medication aligned to the HCPCS J Code: J8670 for billing, pricing, and reimbursement purposes in the United States. This Anti-Emetic medication is administered via the oral route and manufactured by Tersera Therapeutics Llc.

According to CMS Drug Use Information: Rolapitant is used with other medications to help prevent delayed nausea and vomiting caused by cancer drug treatment (chemotherapy). It works by blocking one of the body's natural substances (substance P/neurokinin 1) that causes vomiting. This drug is not recommended for use in children younger than 2 years due to risk of serious side effects.

Disclaimer: This is a summary and does not contain all possible information about this product. For complete information about this product or your specific health needs, ask your healthcare professional.

NDC Code Information

1 NDC package is crosswalked to J8670. Package detail is available to logged-in subscribers.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
•••••-••••-•• Log in to view	VARUBI

Login to view 1 NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

VARUBI Pricing & Reimbursement

J8670 Private Payer Reimbursement

$2.00 / HCPCS unit as of Jan 2026

National median reimbursement across major commercial payers.

Create an account on PayerPrice for more information →

VARUBI Claims Performance

Claims from Jan 2026 – Aug 2026

Claim Denial Rate 0%

Avg. Days to File 67.0days

Avg. Days to Pay 149.0days

Real-world claims performance from FocalPoint, OnPoint Oncology's reimbursement analytics platform, with claims data accrued at the clearing house level.

Explore J8670 claims analytics on FocalPoint →

VARUBI Medically Unlikely Edits (MUE)

The most billing units of J8670 Medicare will pay for one patient in one day, as published by CMS. 1 unit = 1 mg. The limit is different in the office and the hospital. Use the one for your setting.

Practitioner Office

0 units / day

Not payable in this setting

Hospital Outpatient

180 units / day

= 180 mg per day

MAI 3 · Date of Service Edit: Clinical. Per-day limit based on clinical expectations; excess units are denied but may be appealed with documentation of medical necessity. See all MUE limits →

Not on the CMS JW / JZ list

CMS does not include Varubi (J8670) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8670. Wastage billing guide →

VARUBI Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Nausea and Vomiting Associated with Cisplatin-Based Highly Emetogenic Cancer Chemotherapy Nausea and Vomiting Associated with Moderately Emetogenic Cancer Chemotherapy and Combinations of Anthracycline and Cyclophosphamide

Drug Class

Breast Cancer Resistance Protein Inhibitors [MoA]Cytochrome P450 2D6 Inhibitors [MoA]Neurokinin 1 Antagonists [MoA]P-Glycoprotein Inhibitors [MoA]Substance P/Neurokinin-1 Receptor Antagonist [EPC]

Frequently Asked Questions

Is there an available Varubi billing and coding guide?

Our team has not identified a manufacturer-published source of billing and coding information for VARUBI.

Are there any available Varubi patient assistance programs?

VARUBI patient assistance information can be found through Tersera Therapeutics. Visit Here →

Where can I find Varubi prescribing information?

VARUBI prescribing information can be found at the link below: Visit Here →

Where can I find Varubi side effect information?

Information regarding VARUBI's side effects can be found at MedlinePlus Visit Here →

Does billing VARUBI require JZ/JW wastage modifiers?

CMS does not include VARUBI (J8670) on its list of HCPCS pertaining to single-dose containers. Per CMS guidelines, the JZ/JW wastage modifiers may not apply when billing J8670. For more information, visit the link below.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.